Divis Laboratories Ltd

Divi's Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Divis Laboratories Ltd

₹ 4,550 -0.43%
03 Jul 9:09 a.m.
divislaboratories.com BSE: 532488 NSE: DIVISLAB
About

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Key Points

Business Overview:[1]
Company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:
a) Generic APIs:[2]
Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Further, there are 10 APIs in various stages of R&D and pilot scale development
b) Custom Synthesis:[3]
Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years
c) Nutraceutical:[4][5]
Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms

Website BSE NSE
  • Market Cap ₹ 1,20,790 Cr.
  • Current Price ₹ 4,550
  • High / Low ₹ 4,648 / 3,295
  • Stock P/E 75.5
  • Book Value ₹ 511
  • Dividend Yield 0.66 %
  • ROCE 16.4 %
  • ROE 12.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 40.1%

Cons

  • Stock is trading at 8.94 times its book value
  • The company has delivered a poor sales growth of 9.66% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
1,788 1,961 1,988 2,493 2,518 2,255 1,855 1,708 1,951 1,778 1,909 1,855 2,303
1,072 1,109 1,169 1,396 1,414 1,406 1,234 1,299 1,464 1,274 1,430 1,366 1,572
Operating Profit 716 852 818 1,097 1,104 849 621 409 487 504 479 489 731
OPM % 40% 43% 41% 44% 44% 38% 33% 24% 25% 28% 25% 26% 32%
24 36 19 17 52 88 80 113 66 81 86 95 79
Interest 0 0 0 0 0 0 0 0 0 0 1 0 2
Depreciation 70 73 77 80 81 85 86 87 87 93 95 95 95
Profit before tax 669 814 760 1,034 1,076 852 615 435 466 492 469 489 713
Tax % 25% 32% 20% 13% 17% 18% 20% 30% 31% 28% 26% 27% 25%
502 557 606 902 895 702 493 306 321 356 348 358 538
EPS in Rs 18.91 20.99 22.84 33.99 33.70 26.44 18.57 11.53 12.09 13.41 13.11 13.49 20.27
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
2,145 2,532 3,115 3,776 4,064 3,891 4,946 5,394 6,969 8,960 7,768 7,845
1,329 1,514 1,942 2,354 2,615 2,622 3,072 3,568 4,102 5,075 5,397 5,640
Operating Profit 816 1,018 1,173 1,423 1,450 1,269 1,874 1,826 2,867 3,885 2,370 2,205
OPM % 38% 40% 38% 38% 36% 33% 38% 34% 41% 43% 31% 28%
45 68 38 93 72 107 154 186 57 112 344 339
Interest 3 3 3 5 3 2 5 7 2 2 2 3
Depreciation 77 92 136 118 123 142 169 186 256 312 343 378
Profit before tax 781 991 1,072 1,393 1,395 1,231 1,855 1,819 2,666 3,684 2,369 2,163
Tax % 23% 22% 21% 19% 24% 29% 27% 24% 26% 20% 23% 26%
602 773 852 1,126 1,060 877 1,353 1,377 1,984 2,960 1,823 1,600
EPS in Rs 22.67 29.13 32.07 42.41 39.95 33.04 50.96 51.85 74.75 111.52 68.69 60.27
Dividend Payout % 33% 34% 31% 24% 25% 30% 31% 31% 27% 27% 44% 50%
Compounded Sales Growth
10 Years: 12%
5 Years: 10%
3 Years: 4%
TTM: 1%
Compounded Profit Growth
10 Years: 8%
5 Years: 3%
3 Years: -7%
TTM: -12%
Stock Price CAGR
10 Years: 20%
5 Years: 23%
3 Years: 0%
1 Year: 29%
Return on Equity
10 Years: 20%
5 Years: 19%
3 Years: 18%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 27 27 27 53 53 53 53 53 53 53 53 53
Reserves 2,474 2,937 3,469 4,240 5,304 5,872 6,904 7,257 9,242 11,675 12,714 13,518
33 18 27 42 36 63 106 39 5 4 3 3
605 729 883 562 762 797 973 1,183 1,471 1,628 1,654 1,896
Total Liabilities 3,139 3,710 4,405 4,898 6,155 6,785 8,036 8,531 10,771 13,360 14,425 15,470
909 1,222 1,309 1,439 1,559 1,996 2,088 2,782 3,704 4,325 4,723 4,739
CWIP 303 144 218 264 444 120 492 920 711 470 212 778
Investments 408 502 733 803 1,631 1,889 1,946 971 0 72 77 82
1,519 1,842 2,145 2,392 2,521 2,780 3,511 3,858 6,356 8,493 9,413 9,871
Total Assets 3,139 3,710 4,405 4,898 6,155 6,785 8,036 8,531 10,771 13,360 14,425 15,470

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
480 557 826 1,038 1,150 776 954 1,216 1,947 1,912 2,460 1,261
-255 -305 -521 -406 -1,140 -478 -685 -83 75 -2,195 -2,708 -269
-231 -248 -303 -631 2 -314 -246 -1,091 -35 -532 -797 -799
Net Cash Flow -5 3 3 0 13 -17 23 41 1,987 -816 -1,045 193

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 87 104 87 85 81 95 86 96 88 99 84 100
Inventory Days 382 372 350 293 307 314 347 316 329 341 352 371
Days Payable 73 61 68 56 104 96 96 100 117 96 89 96
Cash Conversion Cycle 396 416 368 322 284 313 336 312 300 344 347 376
Working Capital Days 152 159 143 162 151 182 177 182 152 177 188 206
ROCE % 33% 36% 33% 36% 29% 22% 29% 25% 32% 35% 19%

Shareholding Pattern

Numbers in percentages

17 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
51.95% 51.95% 51.95% 51.94% 51.94% 51.94% 51.94% 51.94% 51.93% 51.93% 51.92% 51.92%
20.60% 20.70% 19.30% 18.45% 16.52% 15.40% 15.15% 14.67% 14.69% 14.60% 14.85% 14.68%
16.56% 16.36% 17.73% 18.32% 19.98% 20.75% 20.62% 21.00% 21.15% 21.65% 21.78% 22.10%
0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.05% 0.07% 0.10% 0.10% 0.10% 0.10%
10.89% 11.00% 11.02% 11.28% 11.56% 11.88% 12.23% 12.31% 12.13% 11.72% 11.33% 11.19%
No. of Shareholders 1,93,8832,23,4032,74,5053,09,3973,46,9053,79,2574,14,8474,33,6214,02,1553,73,8603,54,4823,47,629

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls